about
Melanoma: oncogenic drivers and the immune systemPI3K and AKT: Unfaithful Partners in CancerInsulin receptor signaling in normal and insulin-resistant statesmTOR signaling in tumorigenesisA high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells.Discovery of N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides as Highly Active and Selective SGK1 InhibitorsDetermination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomasSGK3 (CISK) may induce tumor angiogenesis (Hypothesis).Identification of components of the host type IA phosphoinositide 3-kinase pathway that promote internalization of Listeria monocytogenes.Tsc1 deficiency impairs mammary development in mice by suppression of AKT, nuclear ERα, and cell-cycle-driving proteins.INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas.Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapyRanibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding diseaseThe serum- and glucocorticoid-induced protein kinase-1 (Sgk-1) mitochondria connection: identification of the IF-1 inhibitor of the F(1)F(0)-ATPase as a mitochondria-specific binding target and the stress-induced mitochondrial localization of endogeINPP4B is an oncogenic regulator in human colon cancer.SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells.The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growthEffects of Caenorhabditis elegans sgk-1 mutations on lifespan, stress resistance, and DAF-16/FoxO regulationCoordinated regulation of serum- and glucocorticoid-inducible kinase 3 by a C-terminal hydrophobic motif and Hsp90-Cdc37 chaperone complexMiR-155 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells through the activation of PI3K/SGK3/β-catenin signaling pathwaysSGK1 affects RAN/RANBP1/RANGAP1 via SP1 to play a critical role in pre-miRNA nuclear export: a new route of epigenomic regulation.AKT-independent PI3-K signaling in cancer - emerging role for SGK3.Relevance of SGK1 in structural, functional and molecular alterations produced by aldosterone in heart.SGK2 promotes hepatocellular carcinoma progression and mediates GSK-3β/β-catenin signaling in HCC cells.Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.Ras-ling with new therapeutic targets for metastasis.MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3.PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.Functional Proteomics Identifies Acinus L as a Direct Insulin- and Amino Acid-Dependent Mammalian Target of Rapamycin Complex 1 (mTORC1) Substrate.The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase.Effects of copper on CHO cells: insights from gene expression analyses.A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation.N-[4-(1H-Pyrazolo[3,4-B]pyrazin-6yl)-phenyl]-sulonamides and Their Use As Pharmaceuticals.Oncogenic Ras differentially regulates metabolism and anoikis in extracellular matrix-detached cells.Phosphorylation of TXNIP by AKT Mediates Acute Influx of Glucose in Response to Insulin.Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.Therapeutic inhibition of SGK1 suppresses colorectal cancer.Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks.
P2860
Q26775598-027B33BB-38CA-4A9F-A21D-E8C228BE0D27Q26781367-0C6DB813-31CD-4F6B-8D37-B70D8CE98294Q26823171-4F9160B4-3B9D-4BC6-B14A-814CE482DA28Q28252695-05EC21A9-61D0-480B-AC8E-AD66BB63AD4AQ30396975-4F20F822-207E-42D2-AAF6-2A66D57DDDF0Q33701389-6F582CEC-8955-4FE4-9678-BD55BC8F6CFEQ34104052-ACEEB84A-A98C-4E49-8F0F-0A2EB782A29EQ35542998-980E8821-0D78-43CF-9D6D-2C9846F39141Q35771966-9C4A7EEB-A135-4C6C-8E58-A5ED097EBB82Q35803551-97751213-093D-4A4A-A1CE-E5B10C9329E2Q35805514-A28A4B50-945A-4E32-9AB9-713CBCDA460EQ36500453-682AEACD-526A-41ED-849E-F08D4B981123Q36545503-8E373EA0-ED94-422B-AAED-E8DDE0C33E8FQ36545796-D12552B8-763D-4B79-831E-9B69889DDE80Q36817646-B8F483DE-FB6C-4838-A930-7FE5FA588E55Q36934467-875016E6-DCC1-4378-B546-C1D57E088056Q37005755-AA721A0C-EC16-448A-AD60-BF985139F7DFQ37085905-82938C82-04BB-4DA3-9E83-A21C0C906AC7Q37223549-0806F5AF-A756-42A6-A236-1DDBAFE92859Q37298076-9DCF6822-3819-4E9A-A865-2FBC0AA68C33Q37596323-48D769CC-EFD5-4DCF-B4A4-BB6E5D4CB84FQ37662358-583A2C9E-0F4C-4D73-A86B-58966B9277E7Q37727820-FB51FA5B-C28A-4729-A4E9-8BFC5EDE5023Q38134714-39558841-8E37-4945-812E-06C9FD0CACA9Q38267480-309AF58B-2EE8-4BBC-866C-34B6F44C6C27Q38699399-52DEA8CF-BBC4-4C82-BD8F-622DE93FDD1AQ38755339-6A45A844-28EF-4244-8FDB-FB008790AB7BQ38805139-02C80BE3-7FF6-465B-B407-3BA12252B3FFQ38905757-D4119DD0-047F-49C8-AB22-5B277F9E6447Q38906407-B16649EF-28A9-4048-99D0-49150353A5B2Q39014611-BD571DB6-B204-4AFB-AA80-165B2B8D8A80Q39021890-F18BBAB3-1629-4FBF-9CB7-7F85215E5B8FQ39036226-CDA4984A-1C3A-4344-BCB9-3A766D4592BEQ39372532-35C5236E-0B1E-4D38-9612-29160EC89F38Q39775301-A2EB092E-BB63-4721-8213-8D221E563FB4Q39968484-4B9DADCE-B2F3-4583-80D8-87AA065A5220Q42510738-45089499-1BDB-4403-828F-31109C112555Q42906858-148A6044-DB00-4A27-9B6A-385CC180F21EQ47161783-E4ADEED2-FBA9-4736-985E-AA72264802CCQ47390421-004208D8-0E13-4FCC-8FD5-170BF6A19AB8
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Second AKT: the rise of SGK in cancer signalling
@ast
Second AKT: the rise of SGK in cancer signalling
@en
Second AKT: the rise of SGK in cancer signalling
@en-gb
Second AKT: the rise of SGK in cancer signalling
@nl
type
label
Second AKT: the rise of SGK in cancer signalling
@ast
Second AKT: the rise of SGK in cancer signalling
@en
Second AKT: the rise of SGK in cancer signalling
@en-gb
Second AKT: the rise of SGK in cancer signalling
@nl
prefLabel
Second AKT: the rise of SGK in cancer signalling
@ast
Second AKT: the rise of SGK in cancer signalling
@en
Second AKT: the rise of SGK in cancer signalling
@en-gb
Second AKT: the rise of SGK in cancer signalling
@nl
P2093
P2860
P921
P3181
P1476
Second AKT: the rise of SGK in cancer signalling
@en
P2093
Karen E Sheppard
Maressa A Bruhn
Ross D Hannan
P2860
P304
P3181
P356
10.3109/08977194.2010.518616
P407
P50
P577
2010-12-01T00:00:00Z